D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
|Videos|May 7, 2011
Donna Berry on Winning Researcher Award
Author(s)Donna L. Berry, PhD, RN
Donna Berry on the Distinguished Researcher Award and Her Advice to Researchers
Advertisement
Donna Berry, PhD, RN, AOCN®, FAAN, Phyllis F. Cantor Center, Dana-Farber Cancer Institute, Boston, MA describes her feelings on winning the 2011 ONS Distinguished Researcher Award and shares her advice for other oncology nurse researchers who are just starting their careers.
View more videos of
Advertisement
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5